Charles Schwab Investment Management Inc. Buys 22,764 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Charles Schwab Investment Management Inc. increased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 1.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,226,398 shares of the medical equipment provider's stock after purchasing an additional 22,764 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.59% of Zimmer Biomet worth $149,253,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZBH. Naples Money Management LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $35,000. Activest Wealth Management raised its stake in shares of Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider's stock worth $42,000 after buying an additional 275 shares during the period. Peoples Bank KS purchased a new position in shares of Zimmer Biomet during the 3rd quarter valued at approximately $48,000. Blue Trust Inc. grew its stake in Zimmer Biomet by 48.4% in the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider's stock valued at $52,000 after acquiring an additional 153 shares during the period. Finally, Quent Capital LLC increased its holdings in Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider's stock worth $63,000 after acquiring an additional 92 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

ZBH stock traded down $0.13 during trading on Friday, reaching $121.31. 772,709 shares of the company's stock were exchanged, compared to its average volume of 1,375,209. The firm has a market cap of $24.96 billion, a PE ratio of 26.26, a P/E/G ratio of 2.19 and a beta of 1.03. The company has a quick ratio of 0.80, a current ratio of 1.66 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $147.50. The company's fifty day moving average price is $124.90 and its 200-day moving average price is $120.56.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The firm had revenue of $1.89 billion for the quarter, compared to analysts' expectations of $1.87 billion. During the same quarter in the previous year, the company earned $1.89 earnings per share. The firm's quarterly revenue was up 3.2% compared to the same quarter last year. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend was Wednesday, March 27th. Zimmer Biomet's dividend payout ratio (DPR) is presently 20.78%.

Insider Buying and Selling at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the business's stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.95% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of research reports. JPMorgan Chase & Co. raised their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the company a "neutral" rating in a research note on Friday, February 9th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Thursday, May 2nd. Evercore ISI upped their price objective on shares of Zimmer Biomet from $125.00 to $130.00 and gave the company an "in-line" rating in a research note on Thursday, April 4th. Citigroup boosted their target price on Zimmer Biomet from $134.00 to $140.00 and gave the stock a "neutral" rating in a report on Wednesday, April 3rd. Finally, Canaccord Genuity Group reiterated a "hold" rating and set a $130.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 23rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $135.40.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.